Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FALCON: SGT-212 in Friedreich's Ataxia
NCT07180355Phase 1Recruiting
- Sponsor
- Solid Biosciences
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of SGT-212 in Friedreich's ataxia (FA) (3 cohorts), sponsored by Solid Biosciences. Primary endpoint: Incidence and Severity of Treatment Emergent Adverse Events at 12 months. Started Oct 2025; status: recruiting.
02
Drugs
SGT-212
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT07180355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07180355.